IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Gopal Thinakaran

Serial No.: 10/051,767

Filed: January 17, 2002

For: FUNCTIONAL SCREENING

Group Art Unit: 1645

Examiner: Unknown

Atty. Dkt. No.: ARCD:364US/MBW

#4
3/26/03

CERTIFICATE OF MAILING
37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:

April 15, 2002
Date

Priya D. Subramony

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10200382/MBW.

Applicant respectfully requests that the listed documents be made of record in the present case.

Respectfully submitted,



Priya D. Subramony
Reg. No. 50,939
Agent for Applicant

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: April 15, 2002

Form PTO-1449 (modified)	Atty. Docket No. ARCD:364US/MBW	Serial No. 10/051,767
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Gopal Thinakaran	
	Filing Date: January 17, 2002	Gr up: 1645

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 1*

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Borchelt, *et al.*, "Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and *in vivo*," *Neuron*, 17:1005-1013, 1996.
	C2	Doan, *et al.*, "Protein topology of presenilin 1," *Neuron*, 17:1023-1030, 1996.
	C3	Naruse, *et al.*, "Effects of PS1 deficiency on membrane protein trafficking in neurons," *Neuron*, 21:1213-1221, 1998.
	C4	Ratovitski, *et al.*, "Endoproteolytic processing and stabilization of wild-type and mutant presenilin," *J. Biol. Chem.*, 272:24536-24541, 1997.
	C5	Saura *et al.*, "Evidence that intramolecular associations between presenilin domains are obligatory for endoproteolytic processing," *J. Biological Chem.*, 274:13818-13823, 1999.
	C6	Saura *et al.*, "The nonconserved hydrophilic loop domain of presenilin (PS) is not required for PS endoproteolysis or enhanced Aβ42 production mediated by familial early onset Alzheimer's, disease-linked PS variants," *J. Biological Chemistry*, 275:17136-17142, 2000.
	C7	Seeger, *et al.*, "Evidence for phosphorylation and oligomeric assembly of presenilin 1," *Proc. Natl. Acad. Sci. USA*, 94:5090-5094, 1997.
	C8	Sisodia, *et al.*, "Function and Dysfunction of the Presenilins," *Am J Hum Genet*, 65:7-12, 1999.
	C9	Thinakaran, "The role of presenilins in Alzheimer's disease," *J Clin Invest*, 104:1321-1327, 1999.
	C10	Thinakaran, "Metabolism of presenilins," *J. of Molecular Neuroscience*, 17:183-192, 2001.

25141629.1

EXAMINER:	DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. ARCD:364US/MBW	Serial No. 10/051,767
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Gopal Thinakaran	
	Filing Date: January 17, 2002	Group: 1645

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 1*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C11	Thinakaran, *et al.*, "Endoproteolysis of presenilin 1 and accumulation of processed derivatives *in vivo*," *Neuron*, 17:181-190, 1996.
	C12	Thinakaran, *et al.*, "Evidence that levels of presenilins (PS1 and PS2) are coordinately regulated by competition for limiting cellular factors," *J. Biol. Chem.*, 272:28415-28422, 1997.
	C13	Thinakaran, *et al.*, "Metabolism of the "Swedish" amyloid precursor protein variant in neuro2a (N2a) cells. Evidence that cleavage at the "beta-secretase" site occurs in the golgi apparatus," *J. Biol. Chem.*, 271:9390-9397, 1996.
	C14	Thinakaran, *et al.*, "Stable association of presenilin derivatives and absence of presenilin interactions with APP," *Neurobiol. Dis.*, 4:438-453, 1998.
	C15	Tomita, *et al.*, "C terminus of presenilin is required for overproduction of amyloidogenic Ab42 through stabilization and endoproteolysis of presenilin," *J. Neurosci.*, 19:10627-10634, 1999.

25141629.1

EXAMINER:	DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.